

13 July 2026

ASX RELEASE

AMPLIA THERAPEUTICS SHAREHOLDER WEBINAR

Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), ("Amplia" or the "Company"), is pleased to announce it will be hosting a shareholder webinar on Tuesday 14th July 2026 at 11am AEST / 9am AWST.

The webinar will be hosted by Amplia's Chief Executive Officer and Managing Director, Dr Chris Burns, who will discuss the Company's drug development pathway and clinical strategy.

Shareholders will have the opportunity to ask questions live during the webinar, although are encouraged to submit them in advance via the website.

Webinar Details

Date: Tuesday 14 July 2026

Time: 11am AEST / 9am AWST

Registration link: <https://ampliatx.com/webinars/exkkjy-amplia-therapeutics-shareholder-webinar>

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

U.S. Contact:

Robert Giordano
rjgiordano@ggrouplifesciences.com
+1 917 327 3938

Media Contact:

Haley Chartres, H[^]CK Director
haley@hck.digital
+61 423 139 163

U.S. Media:

media@ampliatx.com

ABN 16 165 160 841

+61 (0) 3 9123 1140 | info@ampliatx.com
Level 5, 90 William Street, Melbourne VIC 3000 Australia

www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [X](#) (@ampliatx) and [LinkedIn](#).